Immutep Limited (PRRUF) Stock Price & Analysis
Immutep Limited (PRRUF) — price $0.02 (0.00%), as of the Nov 19, 2026 trading session; market cap $29.5M.
Educational signal · not a buy or sell recommendation · How to read this
Immutep Limited · PRRUF
Immutep Limited (PRRUF) is an Australian biotechnology firm focused on developing immunotherapeutic pharmaceuticals targeting cancer and autoimmune diseases. The company is known for its lead product, eftilagimod alpha, currently in advanced clinical trials.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.02 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0168 – $0.3338 | |
| Market capitalisation | $29.5M | — |
| Shares traded on the day | 20.0K |
Price & events
Other perspectives
Council score for Immutep (PRRUF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 5, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 2, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 2, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Immutep (PRRUF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Immutep Limited (PRRUF) is the company analyzed here. It employs 1,027 people and is led by Marc Voigt. In Q4 FY2026 it reported revenue of A$10M and net income of -A$34M. The market values it at $29.5M.
What do the latest results show for Immutep (PRRUF)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of A$10M. Against analyst estimates the company has EPS beat 3 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | A$10M | -A$34M | -A$0.02 (diluted) |
| Q2 FY2026 | A$4M | -A$45M | -A$0.03 (diluted) |
| Q4 FY2025 | A$948,051 | -A$20M | -A$0.01 (diluted) |
| Q2 FY2025 | A$3M | -A$22M | -A$0.02 (diluted) |
What are the financial strengths and risks for Immutep (PRRUF)?
Short answer · as of
The distress and quality screens read Altman Z -9.86 · Piotroski F 3. Trailing ratios: ROE -98.9% · ROA -95.2% · current ratio 5.69.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -9.86 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-98.9%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PRRUF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PRRUF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Immutep (PRRUF)
These answers are editorial: 1 of these 8 answers is drawn from the PRRUF research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is PRRUF a good stock to buy?
Stock Expert AI does not rate PRRUF buy, sell or hold. Immutep Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PRRUF stock price today?
The last price recorded for Immutep Limited (PRRUF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for PRRUF?
Immutep Limited faces several risks, including regulatory hurdles that could impact the approval timelines of its clinical trials and products.
What are the key factors to evaluate for PRRUF?
Evaluate PRRUF on fundamentals, analyst consensus, and risk factors. No dividend yield as the company reinvests earnings into R&D for its innovative pipeline. Not financial advice.
How frequently does PRRUF data refresh on this page?
PRRUF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PRRUF's recent stock price performance?
Immutep Limited (PRRUF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline targeting significant unmet medical needs in oncology and autoimmune diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PRRUF overvalued or undervalued right now?
Immutep Limited (PRRUF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PRRUF before investing?
Before investing in Immutep Limited (PRRUF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com